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Introduction {#sec1}
============

In mammalian cells, the Golgi apparatus is characterized by a multilayer stacked structure of ∼5--7 flattened cisternal membranes, and stacks are often laterally linked to form a ribbon located in the perinuclear region of the cell ([@bib49], [@bib57]). The exact mechanism of Golgi stack formation is not fully understood, but it has been shown that the Golgi re-assembly stacking protein of 55 kDa (GRASP55, also called GORASP2) and its homolog GRASP65 (GORASP1) play essential roles in Golgi stacking ([@bib58], [@bib67]). Both GRASPs are peripheral membrane proteins that share similar domain structures and overlapping functions ([@bib57]). GRASP65 is predominantly concentrated in the cis Golgi, whereas GRASP55 is localized on *medial-trans* cisternae. Both GRASPs form *trans*-oligomers through their N-terminal GRASP domains that "glue" adjacent Golgi cisternae together into stacks ([@bib58], [@bib61]) and ribbons ([@bib11], [@bib40]). GRASP oligomerization is regulated by phosphorylation; mitotic phosphorylation of GRASP55 and GRASP65 at the C-terminal serine/proline-rich (SPR) domain inhibits oligomerization and results in Golgi cisternal unstacking and disassembly ([@bib52], [@bib56], [@bib61]).

The Golgi exhibits different morphology in different cell types and tissues as well as under different conditions. For example, in many secretory cells such as Brunner\'s gland of platypus, the Golgi forms large, well-formed stacks ([@bib27]), whereas electron micrographs show reorganization of Golgi membranes in prolactin cells of female rats upon cessation of a sucking stimulus ([@bib41]). In neurons, increased neuronal activity causes dispersal of the Golgi at the resolution of light microscopy ([@bib54]). In Alzheimer disease, the Golgi membranes are dispersed and fragmented in neurons from human brain and mouse models ([@bib22]). Golgi fragmentation is also observed in other neurodegenerative diseases, including Parkinson ([@bib34]) and Huntington ([@bib17]) diseases and amyotrophic lateral sclerosis (ALS) ([@bib13], [@bib15], [@bib35]). In addition, the Golgi has also been shown to be fragmented in lung, prostate, and breast cancers ([@bib39], [@bib45], [@bib48]). A plausible hypothesis is that the Golgi adjusts its structure and function in response to different physiological and pathological conditions; however, the molecular mechanisms that control Golgi structure and function under disease conditions are so far not well understood.

The Golgi structure can be modulated experimentally such as by molecular manipulations of GRASP55 and GRASP65. Microinjection of antibodies against GRASP55 or GRASP65 into cells inhibits post-mitotic stacking of newly formed Golgi cisternae ([@bib58], [@bib59]). Knockdown (KD, by siRNA) or knockout (KO, by CRISPR/Cas9) of either GRASP reduces the number of cisternae per stack ([@bib47], [@bib51]), whereas simultaneous depletion of both GRASPs causes fragmentation of the entire Golgi stack ([@bib5], [@bib61]). Expression of non-phosphorylatable GRASP65 mutants enhances Golgi stacking in interphase and inhibits Golgi disassembly in mitosis ([@bib51]). Because GRASPs play critical roles in Golgi structure formation, it is reasonable to speculate that physiological and pathological cues may trigger Golgi fragmentation through GRASP55/65 modification, such as phosphorylation ([@bib1], [@bib29]). Using GRASPs as tools to manipulate Golgi stack formation, it has been demonstrated that Golgi cisternal unstacking accelerates protein trafficking but impairs accurate glycosylation and sorting ([@bib5], [@bib62]). In addition, GRASP depletion also affects other cellular activities such as cell attachment, migration, growth, and autophagy ([@bib2], [@bib66], [@bib65]).

Protein kinase C (PKC) is a large family of multifunctional serine/threonine kinases that are activated by signals such as increases in the concentration of diacylglycerol (DAG) and/or intracellular calcium ions (Ca^2+^). In cells, PKCs are mainly cytosolic, but transiently localize to membranes such as endosomes and Golgi upon activation ([@bib7], [@bib9]). Membrane association of PKC is via a C1 domain that interacts with DAG in the membrane. Conventional PKCs (cPKCs) also contain a C2 domain that binds Ca^2+^ ions, which further enhances their membrane association and activity ([@bib37]). Knockdown of atypical PKCs (aPKCs) using siRNA causes a reduction in peripheral ERGIC-53 clusters without affecting the Golgi morphology ([@bib10]). In addition, increased PKC activity has been implicated in cancer ([@bib8], [@bib26]), but the mechanism by which PKC may contribute to invasion, inflammation, tumorigenesis, and metastasis is not fully understood ([@bib16]).

In this study, we performed high-resolution microscopy and biochemistry experiments to determine how the Golgi responds to cellular stresses such as ER stress. Although not all ER stress inducers caused Golgi fragmentation, treatment of cells with the Ca^2+^-ATPase inhibitor thapsigargin (TG) resulted in Golgi fragmentation with a low dose and short time in which ER stress was undetectable, indicating that Golgi fragmentation occurs independently of ER stress. Further experiments demonstrated that TG-induced cytosolic Ca^2+^ spikes activate PKC that phosphorylates GRASP55. Interestingly, inflammatory factors such as histamine modulate the Golgi structure through a similar mechanism. Thus, we have uncovered a novel pathway through which cytosolic Ca^2+^ modulates the Golgi structure and function.

Results {#sec2}
=======

TG Induces Golgi Fragmentation and UPR {#sec2.1}
--------------------------------------

It has been hypothesized that ER stress and the unfolded protein response (UPR) cause Golgi fragmentation and dysfunction through overloading misfolded proteins into the Golgi ([@bib38]). To test this hypothesis, we performed a time course treatment of HeLa cells with a well-known UPR inducer, TG, which specifically blocks the sarcoendoplasmic reticulum Ca^2+^ transport ATPase (SERCA) ([@bib64]) and causes Ca^2+^ dysregulation ([@bib18]). We assessed the Golgi morphology by co-staining the cells for GM130, a cis-Golgi marker, and TGN46, a protein in the *trans*-Golgi network. As shown in [Figures 1](#fig1){ref-type="fig"}A and 1B, the Golgi became fragmented after TG treatment, and the response was linear over time ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#mmc1){ref-type="supplementary-material"}A). Although Golgi fragmentation was more obvious after a longer treatment, it became detectable in shorter treatments such as 10 min. More careful examination of the Golgi morphology by super-resolution fluorescence microscopy demonstrated that the Golgi ribbon was broken down, as the Golgi appeared as disconnected puncta. The stacks were also defective, as indicated by the separation of GM130 and TGN46 signals ([Figures 1](#fig1){ref-type="fig"}C and 1D).Figure 1TG Induces Golgi Fragmentation and UPR(A) Short-term TG treatment causes Golgi fragmentation. HeLa cells were treated with 250 nM TG, fixed at the indicated time points, and stained for GM130 (cis-Golgi) and TGN46 (*trans*-Golgi). Scale bar, 20 μm.(B) Quantitation of (A) for cells with fragmented Golgi using GM130 as the Golgi marker.(C and D) Super-resolution images of DMSO- (C) and TG-treated (D) HeLa cells. Cells were treated with 2 μM TG for 1 h, stained as in (A), and imaged with a Leica SP8 STED microscope. Indicated areas are enlarged and shown on the right as merged GM130 (green) and TGN46 (red). To quantify Golgi unstacking in these images, relative fluorescence intensity was plotted along a random line through the Golgi region. Note the agreement in peaks in control (C) and relative disagreement in peaks in the TG-treated cell (D). Scale bar in main images, 5 μm; in inserts, 1 μm.(E) Longer term TG treatment results in ER stress. Cells treated as in (A) were analyzed by Western blot of indicated proteins. Note that TG treatment increases the levels of p-eIF2α, Bip, and CHOP.(F--G) Quantitation of the ratio of p-eIF2α/eIF2α and the Bip levels from (E), with the no-treatment control normalized to 1.All quantitation results are shown as mean ± SEM from at least three independent experiments; statistical analyses were performed using two-tailed Student\'s *t*-tests (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001).

To correlate Golgi fragmentation with UPR, we performed Western blot of TG-treated cells to assess the levels of several UPR markers, including phosphorylated eukaryotic translation initiation factor 2A eIF2α (p-eIF2α), the ER chaperone binding of immunoglobulin protein (Bip), and the CCAAT-enhancer-binding protein homologous protein (CHOP). As shown in [Figures 1](#fig1){ref-type="fig"}E--1G, longer term TG treatment, for example, 2 h or longer, caused UPR, as indicated by the increase of all three markers. When the treatment was reduced to 30 min, only the p-eIF2α level increased, whereas Bip and CHOP did not change. This indicates that the minimal time for UPR to occur is ∼30 min under our experimental conditions. Consistently, no significant increase in the level of any of these UPR markers was detected when the treatment was reduced to below 30 min. Interestingly, the Golgi in a significant proportion of cells was fragmented at this time. Golgi fragmentation was obvious with 10-min TG treatment when UPR was undetectable and became more prevalent at 30-min treatment ([Figures 1](#fig1){ref-type="fig"}A and 1B). The fact that Golgi fragmentation occurs earlier than UPR indicates that Golgi fragmentation is unlikely a downstream effect of ER stress, but rather occurs independently of UPR.

It is worth mentioning that TG treatment did not affect the level of key Golgi structural proteins, including the Golgi stacking proteins GRASP55 and GRASP65, the Golgi tethering protein GM130, and the Golgi SNARE Gos28 ([Figure 1](#fig1){ref-type="fig"}E), indicating that TG induces Golgi fragmentation likely through modification rather than degradation of Golgi structural proteins. In addition, TG-induced Golgi fragmentation is reversible; when TG was washed out, the Golgi structure gradually returned to its normal shape ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D). Consistently, TG-treatment did not induce apoptosis as shown by Annexin V staining. In contrast, staurosporine treatment, which is known to induce apoptosis, increased Annexin V cell surface staining ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). In addition, TG treatment did not seem to affect the organization of the actin and microtubule cytoskeleton ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G).

Tunicamycin or Dithiothreitol Treatment Induces UPR but Not Golgi Fragmentation {#sec2.2}
-------------------------------------------------------------------------------

To test whether the hypothesis that Golgi fragmentation occurs independently of UPR applies only to TG treatment or also to other ER stress inducers, we repeated the same set of experiments by treating cells with tunicamycin (Tm), an antibiotic that induces ER stress by inhibiting N-glycosylation and the accumulation of misfolded proteins in the ER lumen. Tm treatment did not affect the Golgi morphology after 360 min, as indicated by the GM130 and TGN46 signals ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). Further analysis of Tm-treated cells by electron microscopy (EM) also did not reveal any significant changes in the Golgi structure ([Figure S2](#mmc1){ref-type="supplementary-material"}D). The treatment indeed induced UPR, as indicated by the robust increase in the p-eIF2α, Bip, and CHOP levels, in particular after 120 min ([Figures S2](#mmc1){ref-type="supplementary-material"}E--S2G). Six-hour Tm treatment increased the width of the ER cisternae and caused ER fragmentation ([Figure S2](#mmc1){ref-type="supplementary-material"}H). As Tm, dithiothreitol (DTT) treatment also did not cause Golgi fragmentation, although Bip and CHOP levels increased significantly after 120 min of treatment ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). We also performed super-resolution microscopy to examine the Golgi structure in parallel after Tm, DTT, or TG treatment. Similar to that observed in control cells, the Golgi structure is intact in Tm- and DTT-treated cells, with extensive overlap between *cis*- and *trans*-Golgi markers, whereas TG treatment caused not only fragmentation of the Golgi structure but also separation of *cis*- and *trans*-Golgi markers ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). Taken together, these results indicate that ER stress is unlikely a direct cause of Golgi fragmentation.

TG Induces Golgi Fragmentation Prior to UPR Through Elevated Cytosolic Ca^2+^ {#sec2.3}
-----------------------------------------------------------------------------

We next sought to decouple the Golgi stress response from UPR after TG treatment. As a complementary approach to the timecourse experiment shown in [Figure 1](#fig1){ref-type="fig"}, we titrated TG (1--250 nM) in the treatment. Here we treated cells for 20 min, a time point prior to UPR becoming detectable when cells were treated with 250 nM TG ([Figure 1](#fig1){ref-type="fig"}). The results showed that Golgi fragmentation increased linearly in response to the increasing TG concentration, and importantly, TG at low doses (1--250 nM) effectively caused Golgi fragmentation ([Figures 2](#fig2){ref-type="fig"}A and 2B). For comparison, we also assessed UPR in the same cells. As shown in [Figures 2](#fig2){ref-type="fig"}C--2E, treatment of cells with up to 250 nM TG for 20 min did not cause UPR as indicated by the p-eIF2α and Bip levels. These results indicate that TG triggers Golgi fragmentation independent of ER stress. Furthermore, we carried out similar experiments in normal rat kidney (NRK) cells and RAW 264.7 murine macrophages and obtained similar results ([Figure S4](#mmc1){ref-type="supplementary-material"}), indicating that the effect of TG treatment on the Golgi structure is not cell-type specific.Figure 2Low Concentration of TG Induces Golgi Fragmentation Prior to UPR Through Elevated Cytosolic Ca^2+^(A) HeLa cells were treated with the indicated concentrations of TG for 20 min and stained for GM130. Scale bar, 20 μm.(B) Quantitation of cells with fragmented Golgi in (A).(C) Cells treated with TG as in (A) were analyzed by Western blots.(D and E) Quantitation of p-eIF2α/eIF2α and Bip in (C) from five independent experiments.(F) BAPTA-AM inhibits TG-induced Golgi fragmentation. HeLa cells treated with 100 nM TG for indicated times with or without 60 μM BAPTA-AM (B/AM) and stained for GM130. Scale bar, 20 μm.(G) Quantitation of (F) from three independent experiments. Statistical analyses were performed using two-tailed Student\'s t tests (∗, p ≤ 0.05; ∗∗, p ≤ 0.01; ∗∗∗, p ≤ 0.001).(H) Electron micrographs of Golgi profiles in HeLa cells treated with 250 nM TG and B/AM for 20 min. Note that the Golgi is comprised of bulbous saccules in the TG-treatment, whereas in the B/AM pretreated cells the cisternae appear straight and well-stacked. Asterisks (∗) indicate nuclei. Scale bar, 0.5 μm.(I) Quantitation of the morphological features of Golgi stacks on the EM images in (H). For statistics, B/AM and TG were compared with DMSO treatment, whereas TG + B/AM was compared with TG treatment.

We next asked how TG treatment induces Golgi fragmentation. Knowing that TG increases cytosolic Ca^2+^ ([@bib21]), we employed the membrane permeable Ca^2+^ chelator BAPTA-AM to test whether TG induces Golgi fragmentation through cytosolic Ca^2+^. We pre-treated cells with BAPTA-AM alone (60 μM) for 30 min and then with or without TG (100 nM) for 0, 15, 30, and 60 min ([Figures 2](#fig2){ref-type="fig"}F and 2G). The result showed that BAPTA-AM significantly prevented TG-induced Golgi fragmentation, whereas BAPTA-AM alone did not affect the Golgi morphology. Subsequent EM analysis confirmed TG-induced Golgi fragmentation and its rescue by BAPTA-AM ([Figures 2](#fig2){ref-type="fig"}H and 2I). TG treatment reduced the number of cisternae per stack and the length of cisternae but increased the number of vesicles surrounding each stack. These effects were largely abolished by the addition of BAPTA-AM. These results demonstrated that cytosolic Ca^2+^ is required for TG-induced Golgi fragmentation. Consistent with this notion, treatment of cells with a Ca^2+^ ionophore, ionomycin (Io), also caused Golgi fragmentation ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Therefore, the driving force behind TG-induced Golgi fragmentation is the elevated cytosolic Ca^2+^.

TG-Induced Golgi Fragmentation Increases Protein Trafficking in the Golgi {#sec2.4}
-------------------------------------------------------------------------

As GRASP-depletion-mediated Golgi destruction affects Golgi functions such as protein trafficking ([@bib2], [@bib62]), we examined the effect of TG treatment on the trafficking of the vesicular stomatitis virus glycoprotein (VSV-G) using the well-established RUSH system ([@bib6]). Cells were transfected with a plasmid that encodes both the invariant chain of the major histocompatibility complex (Ii, an ER protein) fused to core streptavidin and VSV-G fused to streptavidin-binding peptide (SBP). Under growth conditions without biotin, the interaction between streptavidin and SBP retains VSV-G in the ER. Upon the addition of biotin, this interaction is disrupted, resulting in synchronous release of the VSV-G reporter from the ER to the Golgi. Because VSV-G is a glycoprotein, we used endoglycosidase H (EndoH) to distinguish its core (ER and *cis* Golgi) and complex (*trans* Golgi and post-Golgi) glycosylation forms as an indicator of trafficking. As shown in [Figure 3](#fig3){ref-type="fig"}A, TG treatment first slightly decreased VSV-G trafficking at 15-min release but then increased VSV-G trafficking at 60 and 90 min compared with DMSO control. Our previous studies showed that VSV-G reaches the cis Golgi at 15--20 min and *trans* Golgi at ∼90 min ([@bib5], [@bib30]). These results suggest that TG treatment may delay VSV-G release possibly by slowing down its folding; but once it reaches the cis Golgi, VSV-G trafficking across the Golgi stack is significantly accelerated. Monensin (Mo) is known to disrupt the Golgi structure and blocks TGN exit ([@bib12]) and thus was used as a control. As expected, monensin treatment resulted in VSV-G accumulation in the Golgi ([Figures 3](#fig3){ref-type="fig"}A--3C).Figure 3TG-Induced Golgi Fragmentation Has Minor Effect on Protein Trafficking(A) Cells were transfected with the Str-li_VSVG wt-SBP-EGFP plasmid for 16 h followed by a 30-min treatment with DMSO, 250 nM TG, or 10 μM monensin (Mo) at 37°C. Cells were then incubated with complete medium containing 40 μM biotin (chase) for the indicated times, lysed and treated with (+) or without (−) EndoH, and analyzed by Western blot for GFP.(B) Quantification of (A) for the percentage of EndoH-resistant VSV-G from three independent experiments. Quantitation results are shown as Mean ± SEM. Statistical analyses were performed using two-tailed Student\'s *t*-tests by comparing with the control (∗p ≤ 0.05).(C) Representative images of (A) showing the subcellular localization of VSVG-EGFP at indicated time points after biotin chase. Scale bar, 20 μm.(D) Fluorescent images showing the subcellular localization of ManII-GFP in cells treated with DMSO (Ctrl) or 250 nM TG at the indicated time points of BFA washout. ManII-GFP appears in the Golgi area beginning at 60 min, whereas this takes longer in control cells. Scale bar, 20 μm.

To confirm these results using an alternative approach, we treated cells with Brefeldin A (BFA) to accumulate ManII-GFP in the ER. We then washed out BFA and analyzed ManII-GFP in ER-to-Golgi trafficking. The results showed that ManII-GFP started to accumulate in the Golgi at 60 min of BFA washout in the presence of TG, whereas the same observation occurred at 90 min in the control ([Figure 3](#fig3){ref-type="fig"}D).

TG Induces Golgi Fragmentation Through PKCα Activation {#sec2.5}
------------------------------------------------------

Given that phosphorylation of Golgi structural proteins has been shown to cause Golgi fragmentation in physiological conditions such as in mitosis ([@bib51], [@bib58], [@bib61]), as well as in pathological conditions such as in Alzheimer disease ([@bib23]), we explored the possibility that phosphorylation of Golgi structural proteins may play a role in TG-induced Golgi fragmentation. We treated cells with staurosporine, a non-selective kinase inhibitor, and a number of specific inhibitors of calcium-related kinases such as protein kinase Cs (PKCs) and Ca^2+^/calmodulin-dependent protein kinases (CAMKs). As shown in [Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D, staurosporine significantly reduced Golgi fragmentation in TG-treated cells. In addition, Bisindolylmaleimide I (BIM1), a selective PKC inhibitor, and KN-93, an inhibitor of CAMKII, also partially reduced Golgi fragmentation in TG-treated cells, whereas the myosin light-chain kinase inhibitor ML-7 and the protein kinase A (PKA) inhibitors H-89 and PKI had no such effects ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S5](#mmc1){ref-type="supplementary-material"}C, and S5D). These results suggest that either PKC and/or CAMKII is involved in TG-induced Golgi fragmentation. Because both BIM1 and KN-93 inhibitors have pleiotropic effects, we selected two alternative drugs, Gö6976 and KN-62, to inhibit PKC and CAMKII, respectively. Although Gö6976 inhibited TG-induced Golgi fragmentation effectively, KN-62 had no effect ([Figures 4](#fig4){ref-type="fig"}A and 4B), suggesting a major role of PKC in TG-induced Golgi fragmentation.Figure 4TG induces Golgi Fragmentation through PKCα(A) Inhibition of PKC reduces TG-induced Golgi fragmentation. HeLa cells were pre-treated with DMSO, BAPTA-AM (B/AM, 60 μM for 10 min), staurosporine (STS, general kinase inhibitor, 2 μM for 10 min), KN-62 or KN-93 (CAMKII inhibitors, 10 μM and 5 μM, respectively, 10 min), or BIM1 or Gӧ6976 (PKC inhibitors, 2 μM and 4 μM, respectively, 10 min), and then with 250 nM TG for 20 min followed by immunostaining of GM130 and TGN46. Scale bar, 20 μm.(B) Quantitation of cells in (A) with fragmented Golgi based on the GM130 pattern in the cell.(C) HeLa cells were treated with 100 nM PMA for 1 h; 4-alpha-PMA of the same concentration was used as a control. Scale bar, 20 µm.(D) Quantitation of cells with fragmented Golgi in (C).(E) Cells treated as in (C) were analyzed by Western blot to show that PMA treatment does not change the PKCα expression level.(F) Activation of ectopically expressed PKCα triggers its Golgi localization (indicated by "→") and Golgi fragmentation (∗). Cells transfected with GFP or PKCα-GFP were treated with 100 nM PMA or 4-alpha for 1 h. Note the fragmented Golgi in these cells upon PMA treatment. Scale bar, 20 μm.(G) Quantitation of cells in (F) with fragmented Golgi.(H) Western blot of cells from (F) showing that ectopic PKC expression does not alter the endogenous PKCα expression level.(I) HeLa cells were transfected with control (Ctrl-i) or PKC-specific siRNA for 48 h and then treated with 250 nM TG for 20 min. Cells were fixed and stained for GM130 (green) to show the Golgi structure. Scale bar, 20 μm.(J) Quantitation of Golgi fragmentation of cells in (I).(K) Cells in (I) were blotted for endogenous PKCα to evaluate the siRNA knockdown efficiency.All quantitation results are shown as Mean ± SEM from three independent experiments. Statistical analyses were performed using two-tailed Student\'s *t*-tests (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; NS, non-significant).

To further confirm that PKC activation causes Golgi fragmentation, we treated cells with phorbol 12-myristate 13-acetate (PMA), a widely used PKC activator, and its inactive enantiomer, 4-alpha-phorbol myristate acetate (4-alpha). The results showed that 4-alpha had no effect on the Golgi structure, whereas PMA treatment caused Golgi fragmentation ([Figures 4](#fig4){ref-type="fig"}C and 4D), although 4-alpha and PMA had no effect on the level of PKC expression ([Figure 4](#fig4){ref-type="fig"}E). In addition, expression of CAMKIIβ had no effect on the Golgi morphology ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). There have been reports that activation of MAPK/ERK or PKD signaling causes Golgi fragmentation ([@bib19], [@bib20]), we therefore inhibited these two kinases with U0126 or H-89, respectively. Pre-treatment of cells with these kinase inhibitors did not prevent Golgi fragmentation upon the addition of TG ([Figures S5](#mmc1){ref-type="supplementary-material"}G and S5H). Taken together, these results indicate that TG induces Golgi fragmentation through PKC activation.

PKC has multiple isoforms including α, βI, βII, γ, δ, ϵ, η, ζ, and ι ([@bib24]). To identify the PKC isoform responsible for TG-induced Golgi fragmentation, we expressed GFP-tagged PKC isoforms, including all four known classical PKC (cPKC) isoforms (α, βI, βII, γ) that respond to Ca^2+^ stimuli, one from the non-calcium responsive novel PKC (nPKC, δ) and one from the atypical PKC (nPKC, ζ) subfamily ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). To enhance the activity of expressed PKC, we also treated cells with PMA, using 4-alpha as a control. The results showed that expression of PKCα and treatment of cells with PMA increased Golgi fragmentation ([Figures 4](#fig4){ref-type="fig"}F--4H, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B). Interestingly, in addition to the localization to the plasma membrane as previously reported ([@bib4]), wild-type PKCα-GFP was also concentrated on the Golgi upon PMA treatment, as indicated by the colocalization with GM130 ([Figures 4](#fig4){ref-type="fig"}F and [S6](#mmc1){ref-type="supplementary-material"}B), whereas other PKC isoforms, or the inactive PKCα K368R mutant ([@bib3]), did not show the same phenotype ([Figures 4](#fig4){ref-type="fig"}F and [S6](#mmc1){ref-type="supplementary-material"}B--S6D). To further specify that PKCα mediates TG-induced Golgi fragmentation, we knocked down PKCα in cells with siRNA. The results showed that PKCα depletion reduces Golgi fragmentation after TG treatment ([Figures 4](#fig4){ref-type="fig"}I--4K). Taken together, these results demonstrate that PKCα activation causes Golgi fragmentation.

PKCα Induces Golgi Fragmentation Through GRASP55 Phosphorylation {#sec2.6}
----------------------------------------------------------------

Because activated PKCα localizes to the Golgi, we thought it might phosphorylate Golgi structural proteins. To identify potential PKCα targets on the Golgi, we performed gel mobility shift assays on a number of Golgi structural proteins, tethering factors, and SNARE proteins after TG treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}E). To ensure that the band shift was caused by phosphorylation, we also applied staurosporine (2 μM for 10 min prior to TG treatment) to TG-treated cells to broadly inhibit phosphorylation. Among the proteins tested, GRASP55 and GRASP65 showed a smear above the main bands ([Figure S6](#mmc1){ref-type="supplementary-material"}E), indicating a partial phosphorylation of the proteins. To increase the resolution of phosphorylated proteins we utilized phos-tag gels, which showed GRASP55, but not GRASP65, to be significantly shifted up after TG treatment (250 nM, 1 h) ([Figure S6](#mmc1){ref-type="supplementary-material"}F). TG-induced mobility shift of GRASP55 was not seen upon Tm treatment ([Figure 5](#fig5){ref-type="fig"}A, lanes 2 vs. 3) and was less dramatic than that by nocodazole (Noc) treatment that blocks cells in mitosis when GRASP55 is fully phosphorylated ([Figure 5](#fig5){ref-type="fig"}A, lanes 3 vs. 4) ([@bib61]), indicating that TG induced partial phosphorylation of GRASP55. The mobility shift of GRASP55 triggered by TG treatment was abolished by the addition of staurosporine ([Figure 5](#fig5){ref-type="fig"}C, lanes 4 vs. 3; [Figure S6](#mmc1){ref-type="supplementary-material"}F, lanes 3 vs. 2), validating the mobility shift by phosphorylation. In addition, incubation of purified recombinant GRASP55 with purified PKCα caused GRASP55 phosphorylation, confirming that PKCα can directly phosphorylate GRASP55 ([Figure 5](#fig5){ref-type="fig"}D). In this experiment, PKCα was also autophosphorylated ([Figure 5](#fig5){ref-type="fig"}D). Taken together, these results demonstrate that TG treatment activates PKCα, which subsequently phosphorylates GRASP55.Figure 5TG Induces Golgi Fragmentation through GRASP55 Phosphorylation(A) GRASP55 is phosphorylated upon TG treatment. HeLa cells treated with Tm, TG, or nocodazole (Noc) were analyzed by phos-tag gels and Western blot. Note the mobility shift of GRASP55 upon TG treatment compared with control (Ctrl). Nocodazole-arrested mitotic cells were used as a positive control for GRASP55 phosphorylation.(B) TG-induced GRASP55 mobility shift is abolished by kinase inhibition. Cells were pre-treated with 2 μM staurosporine (STS) for 10 min and then with 250 nM TG for 1 h followed by analysis with phos-tag gels and Western blot.(C) Quantitation of GRASP55 phosphorylation in TG-treated cells. The intensity of the phosphorylated (upper) band was quantified by densitometry analysis and plotted relative to the intensities of the full length (lower) band. Shown are the results of relative phosphorylation of GRASP55 from three independent experiments.(D) PKCα phosphorylates GRASP55 *in vitro*. Purified PKCα and GRASP55 were incubated in a kinase buffer with or without ATP as indicated and analyzed by phos-tag gels and Western blot for GRASP55 and PKCα.(E) Mapping the phosphorylation site on GRASP55 by expressing GRASP55 truncation mutants. Indicated GFP-tagged GRASP55 constructs were expressed in HeLa cells. After TG treatment, GRASP55 was analyzed by mobility shift as in (A). Note the mobility shift in lanes 8, 10, and 12.(F) Quantitation of GRASP55 phosphorylation in TG-treated cells from (E).(G) TG-induced Golgi fragmentation is rescued by the expression of non-phosphorylatable GRASP55 proteins. Cells expressing the indicated GRASP55 constructs were stained for giantin. Scale bar, 20 µm.(H) Quantitation of cells in (G) with fragmented Golgi. Results are shown as Mean ± SEM.Statistical analyses were performed using two-tailed Student\'s *t*-tests (∗p ≤ 0.05; ∗∗p ≤ 0.01).

GRASP55 contains an N-terminal GRASP domain that forms dimers and oligomers and a C-terminal SPR domain with multiple phosphorylation sites ([@bib61], [@bib67]). To map the PKCα phosphorylation site on GRASP55, we expressed GFP-tagged GRASP55 truncation mutants ([@bib66]), treated the cells with TG, and determined their phosphorylation. A visible mobility shift of the GRASP55 variants was observed on the mutants possessing amino acids (aa)251-300 but not the truncated forms shorter than aa250 ([Figures 5](#fig5){ref-type="fig"}E and 5F). To further determine the functional consequence of GRASP55 phosphorylation, we expressed these constructs and treated cells with or without TG. The exogenously expressed GRASP55 truncation mutants were targeted to the Golgi as indicated by giantin as a Golgi marker but had no impact on the Golgi structure ([Figure S6](#mmc1){ref-type="supplementary-material"}G). However, when cells were treated with TG, expression of the N-terminal aa250 or shorter reduced TG-induced Golgi fragmentation, whereas expression of N-terminal aa300 or longer had no significant effect ([Figures 5](#fig5){ref-type="fig"}G and 5H). These results demonstrated that phosphorylation of GRASP55 within aa251-300 is important for TG-induced Golgi fragmentation.

Histamine Modulates the Golgi Structure Through the Same Pathway as TG Treatment {#sec2.7}
--------------------------------------------------------------------------------

It is known that histamine activates Ca^2+^-dependent PKC isoforms and upregulates cytokine secretion via the release of calcium from the ER into the cytosol ([@bib33]). It has also been shown that histamine triggers protein secretion and Golgi fragmentation ([@bib43]), but the underlying mechanism has not been revealed. Therefore, we treated HeLa cells with histamine and determined the effect on Golgi morphology. As shown in [Figures 6](#fig6){ref-type="fig"}A and 6B, histamine treatment induced Golgi fragmentation in a dose- and time-dependent manner. More than 40% of cells possessed fragmented Golgi after 100 μM histamine treatment for 1 h, a concentration and time often used in previous studies ([@bib42], [@bib63]). Subsequent EM analysis confirmed that histamine treatment induced alterations in the Golgi structure, including fewer cisternae per stack, shorter cisternae, and an increased number of Golgi-associated vesicles ([Figures 6](#fig6){ref-type="fig"}C, 6D, and [S7](#mmc1){ref-type="supplementary-material"}A).Figure 6Histamine Induces Golgi Fragmentation through PKC Activation(A) HeLa cells were treated with indicated concentrations of histamine for 1 h, stained for GM130, and quantified for the percentage of cells with fragmented Golgi. Shown are the quantitation results.(B) HeLa cells were treated with 100 μM histamine for the indicated times and analyzed as in (A). Note that histamine induced Golgi fragmentation within 2 h.(C) Electron micrographs of Golgi profiles in HeLa cells treated with DMSO control (Ctrl, left panel) or 100 μM histamine for 1 h (right panel). Note the reduced size of the Golgi in histamine-treated cells. Scale bar, 0.5 μm.(D) Quantitation of the morphological features of the Golgi stacks in (C). For statistics, histamine treated cells were compared with control cells.(E) Cells were pre-treated with (+) or without (−) the PKC inhibitor Gö6976 at 37°C for 10 min followed by the addition of 100 μM histamine for 60 min. Scale bar, 20 μm.(F) Quantitation of cells with fragmented Golgi in (E).(G) Expression of the GRASP55-GCaMP7 Golgi Ca^2+^ sensor. HeLa cells transfected with indicated proteins were analyzed by Western blot for GFP.(H) Histamine treatment increases the GRASP55-GCaMP7 signal. HeLa cells were co-transfected with mCherry-GM130 (red) and GRASP55-GCAMP7 (green). Shown are still frames before (left panel) or after (right) histamine was added. Scale bar, 5 µm.(I) TG and ionomycin treatments increase the GRASP55-GCaMP7 signal. HeLa cells expressing GRASP55-GCaMP7 were treated with 100 μM histamine (Hist), 250 nM TG, or 1 μM ionomycin (Io) for 1 h. Shown are the quantitation of the fluorescence intensity before and after the drug was added.All quantitation results are shown as Mean ± SEM. Statistical analyses were performed using two-tailed Student\'s *t*-tests (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001).

It has been previously shown that histamine activates Gβγ, which causes TGN fragmentation ([@bib43]). Because HeLa cells do not express Gβγ, and histamine treatment triggers fragmentation of the entire Golgi stack ([Figures 6](#fig6){ref-type="fig"}C and 6D), the Golgi fragmentation observed in our study may occur through a different mechanism. Indeed, as TG, histamine-induced Golgi fragmentation also depended on PKC, as the addition of the PKC inhibitor Gö6976 reduced histamine-induced Golgi fragmentation ([Figures 6](#fig6){ref-type="fig"}E and 6F). To investigate the functional consequence of histamine treatment on Golgi function, VSV-G trafficking experiments were performed as above. As shown in [Figures S7](#mmc1){ref-type="supplementary-material"}B and S7C, histamine treatment slightly decreased VSV-G trafficking within 45-min release but then began to increase the trafficking speed in the Golgi at later time points. These results demonstrate that histamine treatment affects Golgi structure and function through a similar mechanism as TG.

Although it has been well documented that TG or histamine treatment elevates Ca^2+^ level in the cytosol, whether this is also true for the Ca^2+^ level in the Golgi region has not been reported. To test the effect of TG or histamine treatment on the Ca^2+^ level in the Golgi region in real time, we fused the Ca^2+^ probe GCaMP ([@bib36]) to GRASP55, expressed the GRASP55-GCaMP construct in cells ([Figure 6](#fig6){ref-type="fig"}G), and performed live cell imaging. Treatment of cells with 100 μM histamine caused a robust calcium spike ([Figure 6](#fig6){ref-type="fig"}H; [Video S1](#mmc2){ref-type="supplementary-material"}). Subsequent experiments using this novel Golgi-localized Ca^2+^ probe demonstrated that treatment of cells with TG and Io also significantly elevated the Ca^2+^ level in the Golgi ([Figure 6](#fig6){ref-type="fig"}I). Taken together, our results demonstrated that histamine or TG treatment elevates the Ca^2+^ level in the Golgi region, which subsequently activates PKCα, leading to GRASP55 phosphorylation and Golgi fragmentation. Thus, this study revealed a novel mechanism of how histamine, and perhaps other drugs, modulates Golgi structure and function.

Video S1. Histamine Treatment Induces a Robust Calcium Spike, Related to Figure 6Live cell imaging of HeLa cells expressing both mCherry-GM130 (red) and GRASP55-GCaMP(green) treated with 100 μM histamine. The time when histamine was added is indicated in the video. Note the elevated green signal when histamine was added.

Discussion {#sec3}
==========

In this study, by comparing Golgi fragmentation with ER stress in response to TG, Tm, and DTT treatments, we uncovered a novel signaling pathway through which increased cytosolic Ca^2+^ triggers Golgi fragmentation through PKCα activation and GRASP55 phosphorylation. Significantly, we also demonstrated that histamine modulates the Golgi structure and function via a similar mechanism, which opens a new window through which we can better understand the effect of histamine on cell physiology.

One possible model of Golgi stress is that the expanding capacity of the ER during cellular stress leads to the failure of the Golgi as it is over-burdened with misfolded or improperly folded proteins, affecting its functions such as glycosylation ([@bib38]). However, our results do not support this hypothesis for two reasons. First, although three ER stress inducers, TG, Tm, and DTT, all induce ER stress, only TG treatment causes Golgi fragmentation. Second, TG induces Golgi fragmentation at a low dose and time when UPR is undetectable. These results demonstrate that Golgi fragmentation occurs independently of ER stress, perhaps via the modification of pre-existing cellular materials. Therefore, the Golgi may possess its own mechanism to sense and respond to stress alongside or completely separate from the ER. Furthermore, our study revealed a novel mechanism that coordinates Golgi structure and perhaps function: TG treatment increases cytoplasmic Ca^2+^, which activates PKCα, which subsequently phosphorylates GRASP55, impairing its function in Golgi structure formation. GRASP55 therefore provides the conceptual link between an extracellular cue and Golgi morphological change during stress.

GRASP55 is comprised of an N-terminal GRASP domain (aa1-212) that forms dimers and oligomers and functions as a membrane tether to maintain an intact Golgi structure and an SPR domain (aa212-454) that undergoes post-translational modifications and functions as the regulatory domain of the protein ([@bib61], [@bib67]). Originally, GRASP55 was found to be phosphorylated by ERK2 at T225 and T222 ([@bib20]). Subsequently, additional sites, such as S245 and T249, were identified to be phosphorylated in mitosis, which is required for mitotic Golgi disassembly ([@bib61]). Recently, GRASP55 was discovered to be de-O-GlcNAcylated upon energy or nutrient deprivation and regulates autophagosome maturation ([@bib66], [@bib65]). These results indicate that GRASP55 is an excellent candidate to function as both a sensor and effector of cellular stresses. Thus, GRASP55 is likely a master regulator of Golgi structure formation, function, and stress responses.

Our *in vitro* kinase assay demonstrated that PKCα can directly phosphorylate GRASP55 likely on more than one site. The mobility shift of GRASP55 observed in cells consisted of only one obvious band, whereas the *in vitro* experiment showed two clear bands, suggesting that phosphorylation of GRASP55 in cells might occur less frequently. Using GRASP55 truncation mutants we mapped the site(s) of PKC-mediated phosphorylation to the aa251-300 region. Expression of truncation mutants of GRASP55 that lack this region significantly reduced TG-induced Golgi fragmentation. Previously, it has been shown by mass spectrometry that GRASP55 is phosphorylated on S441 after TG treatment, but the kinase mediating this phosphorylation is unknown ([@bib14]). Although our results are consistent with this previous study, the exact phosphorylation site(s) need further investigation.

Histamine is a neuroendocrine hormone involved in the regulation of stomach acid secretion, brain function, and immune response; many of these functions involve secretion ([@bib25], [@bib42], [@bib63]). The role of histamine in immune response is often through the activation of the downstream kinase PKCα. For example, histamine enhances the secretion of granulocyte-macrophage colony stimulation factor (GM-CSF) and nerve growth factor (NGF) in different cell types, both through a PKCα-dependent mechanism ([@bib46]). Interestingly, histamine promotes HeLa cell proliferation and growth and has been shown to be elevated in cancers where Golgi is fragmented and secretion is enhanced. In our experiments, histamine induced a clear Golgi fragmentation phenotype, confirming a link between histamine and Golgi fragmentation. Additionally, expression of PKCα, but not other PKC isoforms, along with a stimulation with PMA, exhibited an additive Golgi fragmentation effect. Consistent with prior work showing that disassembly of Golgi stacks accelerates protein trafficking ([@bib62]), our findings therefore offer a mechanism for how histamine increases secretion of inflammatory factors.

How Ca^2+^ controls membrane trafficking at the plasma membrane has been well documented in regulated secretion in specific cell types such as neurons, neuroendocrine cells, and mast cells, whereas its role in other cell types is less well known. Ca^2+^ dynamic at the Golgi as well as its role in membrane trafficking at the Golgi is still an understudied area. There are EF-hand Ca^2+^ binding proteins associated in the Golgi. For example, Cab45 is located in the Golgi lumen, whereas Calnuc is found in both cell cytosol and membrane fractions ([@bib32]). At the cis-Golgi, Calnuc binds Gαi and Gαs, which is thought to be important for vesicular trafficking ([@bib31]). There are also P-Type ATPases (SPCAs) such as SPCA1 located in the Golgi that regulate Ca^2+^ homeostasis in the Golgi and control neural polarity ([@bib44], [@bib55]). Our study provided a novel link between thapsigargin and histamine treatment, elevation of Ca^2+^ concentration in the Golgi region, activation of PKC and phosphorylation of Golgi GRASP55, and modification of Golgi structure and function.

Our study revealed that TG induces Golgi fragmentation through increasing cytosolic Ca^2+^ and GRASP55 phosphorylation. A similar case has been described previously in Alzheimer disease, where cytosolic calcium increases by Aβ treatment triggers activation of a cytosolic protease, calpain, which cleaves p35 to generate p25 and activate Cdk5, a cytoplasmic kinase that is highly expressed in neurons ([@bib28]). Subsequently, activated Cdk5 phosphorylates GRASP65 and perhaps other Golgi structural proteins, leading to Golgi fragmentation ([@bib23], [@bib22]). Although PKC and GRASP55 were not the focus in this study, expression of a phosphorylation-deficient mutant of GRASP55 significantly reduced Golgi fragmentation as well as Aβ production. Taken together, our studies indicate that the Golgi is sensitive to cellular stimuli and stresses as in disease conditions,and responds to signaling cues to adjust its structure and function through increasing cytosolic Ca^2+^ and GRASP55 modification. Future studies defining the detailed mechanisms may help understand disease pathologies with Golgi and trafficking defects.

Limitations of the Study {#sec3.1}
------------------------

Phosphorylation occurs more frequently *in vitro* than in cells. The exact phosphorylation site(s) on GRASP55 needs further investigation.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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All data from this study is available upon request.
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Document S1. Transparent Methods and Figures S1--S7
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